** Brokerage BofA Global Research upgrades Trojan condom maker Church & Dwight CHD.N to "buy" from "neutral", raises PT to $125 from $112
** Shares of CHD rise 1.2% to $106.86 premarket
** New PT represents 15.5% upside to the stock's last close
** Brokerage says CHD is well-positioned to perform well in a recession due to its value-focused portfolio and limited exposure to private-label competition
** Brokerage notes that CHD has a strong track record of outperforming the S&P 500 Index in past recessions, with an average beat of 22%
** Brokerage expects co to prioritize volume growth over price increases in a challenging consumer environment
** Following increased spending on marketing and capital projects, the company has seen a boost in its market share through 2024, says BofA
** Ten out of 26 brokerages rate the stock "buy" or higher, 11 rate "hold", 5 rate "sell" or higher and their median PT is $110 as per data compiled by LSEG
** As of last close, CHD stock up 0.83% YTD
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.